39 citations,
November 2017 in “PubMed” This retrospective medical record review described four patients with lichen planopilaris (LPP) treated with low-dose (3 mg/day) naltrexone. The treatment provided benefits such as reduced symptoms of pruritus, decreased clinical evidence of scalp inflammation, and slowed disease progression. All patients tolerated the medication without adverse effects, making it a well-tolerated and cost-effective option. This was the first case series to demonstrate the beneficial effects of low-dose naltrexone for LPP.
4 citations,
January 2019 in “Dermatology Online Journal” Low-dose naltrexone might be a cheap and effective additional treatment for hair loss with scalp discomfort due to its anti-inflammatory effects and few side effects.
2 citations,
January 2023 in “Curēus” Low-dose naltrexone may help reduce redness in certain scalp conditions.
1 citations,
May 2022 in “Journal of Drugs in Dermatology” Low-dose naltrexone and platelet-rich plasma can regrow hair in lichen planopilaris.
January 2018 in “Hair transplant forum international” Naltrexone shows promise as a safe treatment for a type of hair loss called lichen planopilaris.
14 citations,
January 2018 in “Journal of Investigative Dermatology Symposium Proceedings” The document discussed emerging unconventional therapies for alopecia areata (AA), an autoimmune disease with no approved treatments. It highlighted antihistamines, cryotherapy, and low-dose naltrexone (LDN) as potential options, though research on their safety and efficacy was limited. Antihistamines might help due to their anti-inflammatory properties, and cryotherapy showed some promise in small studies, but neither achieved complete hair regrowth. LDN, used for other inflammatory conditions, lacked studies in AA but was being used by some patients and physicians. The document emphasized the need for clinical trials to validate these therapies.
August 2022 in “IntechOpen eBooks” The best treatment for Frontal Fibrosing Alopecia and Lichen Planopilaris combines oral and topical medications to reduce symptoms and stop hair loss.
11 citations,
February 2020 in “Dermatology and therapy” Low-Level Light Therapy significantly reduced inflammation and promoted hair regrowth in patients with Lichen planopilaris.
61 citations,
January 2019 in “American Journal of Clinical Dermatology” The cause of Frontal Fibrosing Alopecia is unclear, diagnosis involves clinical evaluation and various treatments exist, but their effectiveness is uncertain.
13 citations,
April 2022 in “Anais brasileiros de dermatologia/Anais Brasileiros de Dermatologia” The document concludes that more research is needed to find effective treatments for Lichen planopilaris and Frontal fibrosing alopecia.
Liquid nitrogen cryotherapy is an effective treatment for alopecia areata.
25 citations,
April 2019 in “Journal of The American Academy of Dermatology” Using 2% tofacitinib cream with narrowband ultraviolet B improved facial vitiligo by 70% in patients who didn't respond to previous treatments, with no side effects reported.
5 citations,
July 2021 in “Basic & Clinical Pharmacology & Toxicology” Melatonin may protect ear cells from damage caused by nicotine.
37 citations,
April 2019 in “Journal of The American Academy of Dermatology” Some treatments like intralesional steroids and 5α-reductase inhibitors are effective for frontal fibrosing alopecia, but more research is needed.
3 citations,
June 2022 in “Dermatology and therapy” A new botanical treatment improved hair growth and symptoms in lichen planopilaris patients.
3 citations,
November 2020 in “Clinical, Cosmetic and Investigational Dermatology” Early diagnosis and combination therapy, especially with finasteride and dutasteride, are key to managing Frontal Fibrosing Alopecia effectively.
2 citations,
October 2020 in “International Journal of Dermatology” Lichen planopilaris in men often involves scalp redness and itching, with some also having hair loss, mucosal lichen planus, or thyroid disease, and treatment improved symptoms in nearly half of the cases.
April 2023 in “Dermatology practical & conceptual” Tacrolimus solution is effective and well-tolerated for treating inflammatory scalp conditions.
Icosapent ethyl may help treat long-lasting symptoms after COVID-19.
December 2017 in “The journal of investigative dermatology. Symposium proceedings/The Journal of investigative dermatology symposium proceedings” The summit aimed to speed up finding treatments for alopecia areata.
May 2023 in “Clinical and translational neuroscience” Tailored neurorehabilitation programs improve life quality for post-COVID-19 patients.
1 citations,
June 2021 in “Biomolecules & Therapeutics” Activating δ-opioid receptors can help hair grow.
23 citations,
January 2021 in “Journal of Dermatological Science” The document concludes that we need more research to understand Telogen Effluvium and find effective treatments.
5 citations,
September 2021 in “Clinical case reports” GLPLS is a rare skin condition with specific hair loss and skin symptoms.
3 citations,
July 2023 in “International journal of molecular sciences” Stress may contribute to hair loss in alopecia areata by affecting immune responses and cell death in hair follicles.
April 2024 in “Journal of clinical medicine” Effective treatment guidelines for frontal fibrosing alopecia are still unclear.
August 2023 in “Journal of The American Academy of Dermatology” Early treatment is key for permanent hair loss disorders, with options ranging from medications and phototherapy to immunomodulators and antibiotics, depending on severity and type.
August 2021 in “Annals of Agricultural and Environmental Medicine” The article concludes that understanding Frontal Fibrosing Alopecia (FFA) is crucial for effective treatment, which includes medication like 5α-reductase inhibitors and hydroxychloroquine.
July 2021 in “Authorea (Authorea)” Graham-Little Piccardi Lassueur Syndrome is a rare skin condition with specific hair loss and skin symptoms.
October 2020 in “International Journal of Research in Dermatology” The review suggests more research is needed to understand Frontal fibrosing alopecia, a condition causing hairline recession in postmenopausal women.